Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   Pharming   /   Daily Mirror 06 - 11- 2007 !

Aandeel Pharming Group NL0010391025

Laatste koers (eur) Verschil Volume
0,855   +0,002   (+0,18%) Dagrange 0,844 - 0,869 5.295.584   Gem. (3M) 5,5M

Daily Mirror 06 - 11- 2007 !

Volgen
137 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste | Omlaag ↓
  3. [verwijderd] 6 november 2007 14:46
    quote:

    prinsH schreef:

    [quote=zandkoek]
    [quote=relationinformation]
    Ik heb al eens horen zeggen dat 7 nov. de goedkeuring er zou zijn! Dus let op, want dan gaan we snel omhoog!

    [/quote]

    Daar wordt een mens nu toch zo moe van hè...

    Toch geen goedkeuring vóór een vergadering zeker, hou daar nu toch eens over op!

    Voor de rest: laat maar komen... Ná de vergadering bedoel ik dan. Nou moe.
    [/quote]

    En FDA???? hihi

    en dan moet je wel de goede vergadering nemen, die van CHMP en niet COMP
  12. Huppeldepepup 6 november 2007 15:31
    Er zal toch een flink aantal lieden nu al en in de komende dagen zeker een gokje gaan wagen op de uitkomst van de vergadering. Zal de komende dagen vast nog wel 20 of 30 cent oplopen zonder bericht. Vraag is wat verstandig is. Vlak voor de vergadering eruit of ervan uitgaan dat de vergadering positief is en blijven zitten?
  13. [verwijderd] 6 november 2007 15:34
    quote:

    Huppeldepepup schreef:

    Er zal toch een flink aantal lieden nu al en in de komende dagen zeker een gokje gaan wagen op de uitkomst van de vergadering. Zal de komende dagen vast nog wel 20 of 30 cent oplopen zonder bericht. Vraag is wat verstandig is. Vlak voor de vergadering eruit of ervan uitgaan dat de vergadering positief is en blijven zitten?
    Dat hangt van de prijs af. Een gok boven de 4 euro laat ik aan mij voorbij gaan.
  14. [verwijderd] 6 november 2007 15:41
    About Plasma and Plasma Therapies

    Plasma is the portion of blood that remains after red cells, leukocytes and platelets are removed. Plasma consists of water, salts, enzymes, antibodies and other proteins. Plasma proteins perform a variety of roles, including clotting blood, fighting diseases and other critical functions. They are the starting material for a wide range of lifesaving medicines. Other therapies use recombinant DNA technology. With this technology, protein is synthesized in genetically engineered cell lines instead of being extracted from blood.
    Producing plasma-derived products is a unique process where several therapies are created from a single starting material - human plasma. The biological nature of human plasma provides particular challenges to obtaining safe starting material and manufacturing safe and high-quality therapies.
    Our therapies are indicated for the treatment of rare diseases such as hemophilia and other bleeding disorders, primary immune deficiency disorders and inherited respiratory disease. Plasma-derived therapeutics can also prevent Rh factor problems in newborns, speed recovery from heart surgery, and help victims of shock and burns recover faster.

    Plasma-derived proteins replace missing components in the blood to allow individuals with these chronic conditions to survive and lead healthier lives.

    From Plasma Donation to Final Product
    Manufacturing plasma therapeutics is a complex, highly sophisticated process that takes about seven months from plasma donation to completion of the finished product. Throughout the manufacturing process, safety and quality are our highest priorities.

    CSL Behring has more than 70 plasma collection centers, eight in Germany and the rest in the United States, all operated by our subsidiary, ZLB Plasma. We are always reaching out to qualified plasma donors.

    Plasmapheresis
    Once donors are qualified, their plasma is collected through a procedure called plasmapheresis. The donor’s blood is drawn through a needle in the arm into a machine that separates blood cells from the plasma. At the end of the donation, the cells are returned to the donor through the same needle. During this process many donors read, watch a movie or relax.
    The first donation is tested to ensure safety and quality and isn’t released for processing until after a second donation is made by the same donor and found to be safe.

    Laboratory
    Serum samples from each unit of plasma are shipped to one of our state-of-the-art testing laboratories in Knoxville, Tenn., and Göttingen, Germany. Although our donors are carefully screened, we use many additional precautions and procedures before we approve the plasma for manufacturing. All plasma samples are tested for HIV, Hepatitis B, Hepatitis C, and other pathogens. Any units that test positive for a virus are discarded.

    Logistics Center
    Frozen plasma is stored in one of our Plasma Logistics Centers (PLCs). While the plasma samples are being tested, the rest of the unit is held in inventory, and all units are carefully tracked. If any problems are found, the plasma is rejected. The PLCs make sure that only units that pass sensitive testing are sent to the manufacturing sites.

    Manufacturing
    CSL Behring operates three manufacturing sites in Bern, Switzerland; Marburg, Germany; and Kankakee, Illinois. At each site, thousands of units of plasma are combined into a plasma "pool" and tested again. Our therapeutics are made using a process called fractionation. Fractionation uses purification methods-including precipitation, centrifugation and column chromatography-to break down plasma into its various proteins, separating out specific proteins for our various therapies. Different products require different means of separation.
    Finally, we package finished therapies for distribution. Regulatory authorities check each lot before approving it for release.

    Economics of Plasma Therapies
    Plasma therapeutics are different from traditional pharmaceuticals in important ways. The starting material is human plasma, not a chemical compound. The cost associated with collecting, testing, storing and transporting this lifesaving starting material is significant. With pharmaceutical chemical compounds, the cost of raw materials typically represents a proportionally smaller portion of the cost of the products. Plasma therapeutics treat small patient populations, while many pharmaceuticals treat millions of patients worldwide. This means that the cost of our therapies are spread over a much smaller base of patients. Further, plasma protein therapies have long planning and production times, often well over 200 days from collection of raw material to finished products for sale reaching the patients.
    To be economically healthy, a company must produce several therapies from each unit of plasma. Revenues from all therapies are needed to cover costs incurred producing them. While companies strive to meet requirements for each plasma therapy, unsold inventory can result in losses.
    Improvements in two key areas can benefit the economic viability of the industry and ensure continued patient access to and choice of therapies.

    First, global harmonization of the stringent regulatory requirements for plasma-derived therapies can lead to more consistency at lower cost of production. Second, reimbursement fees should reflect the unique nature of plasma protein therapeutics and the costs involved in manufacturing safe, effective, life-saving therapies.

    © 2007 CSL Behring
    CSL Behring US | ZLB Plasma | All CSL Behring Web
  15. Huppeldepepup 6 november 2007 15:54
    quote:

    prinsH schreef:

    [quote=Huppeldepepup]
    Er zal toch een flink aantal lieden nu al en in de komende dagen zeker een gokje gaan wagen op de uitkomst van de vergadering. Zal de komende dagen vast nog wel 20 of 30 cent oplopen zonder bericht. Vraag is wat verstandig is. Vlak voor de vergadering eruit of ervan uitgaan dat de vergadering positief is en blijven zitten?
    [/quote]

    Dat hangt van de prijs af. Een gok boven de 4 euro laat ik aan mij voorbij gaan.
    Ik ben bang dat er velen zijn die zo redeneren. Daarom stap ik denk ik ook maar uit op dat niveau. Van winst nemen is nog nooit iemand armer geworden tenslotte.
137 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Update: Gedurfde overnamezet van Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. Pharming verklaart bod op Abliva onvoorwaardelijk
  2. Pharming stemt over nieuwe CEO
  3. Pharming presenteert nieuwe CEO
  4. Fundlogic verkoopt bijna geheel belang in Pharming
  5. Fundlogic flink groter in Pharming
  6. DWS meldt groter belang in Pharming
  7. Morgan Stanley groter in Pharming
  8. CEO: Pharming koopt met KL1333 van Abliva goede kans op blockbuster (video)
  9. RBC verhoogt koersdoel Pharming fors
  10. Afwachtend begin van Super Central Bank-week en we hebben een beursganger